Hepatitis C, Direct-Acting Antivirals
PDL Reference Documents
- Hepatitis C, Direct-Acting Antivirals - Oct 03, 2024
- Hepatitis C DAA Policy Proposal - Apr 07, 2022
- Hepatitis C, Direct-Acting Antivirals - Oct 07, 2021
- Hepatitis C Literature Scan - Jun 04, 2020
- Hepatitis C, DAAs - Sep 26, 2019
- Hepatitis C Direct-Acting Antivirals - Sep 27, 2018
- Hepatitis C Direct-Acting Antivirals Class Update - Sep 28, 2017
- Direct-acting Antivirals for Hepatitis C - Sep 29, 2016
- Hepatitis C Direct-acting Antivirals - Jan 28, 2016
- Hepatitis C Class Update - Jan 29, 2015
- Hepatitis C Class Update - Sep 23, 2014
Drug Use Review Documents
Newsletters
PDL Status Values
Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the
Non-Preferred Drugs in Select PDL Classes prior authorization criteria.
New drugs will be listed as N until reviewed by the P&T Committee and are subject to the
New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.
To request a Prior Authorization, please use this form.
NDC | Brand Name | Generic Name | Form | Strength | PDL Status |
Rebate | Current Drug Use Criteria |
---|---|---|---|---|---|---|---|
00006307401 | ZEPATIER | elbasvir/grazoprevir | TABLET | 50 mg-100 mg | N | Y | Quantity Limit |
00006307402 | ZEPATIER | elbasvir/grazoprevir | TABLET | 50 mg-100 mg | N | Y | Quantity Limit |
00074260028 | MAVYRET | glecaprevir/pibrentasvir | PELET PACK | 50 mg-20 mg | N | Y | Quantity Limit |
00074262501 | MAVYRET | glecaprevir/pibrentasvir | TABLET | 100 mg-40 mg | Y | Y | Quantity Limit |
00074262504 | MAVYRET | glecaprevir/pibrentasvir | TABLET | 100 mg-40 mg | Y | Y | Quantity Limit |
00074262528 | MAVYRET | glecaprevir/pibrentasvir | TABLET | 100 mg-40 mg | Y | Y | Quantity Limit |
00074262584 | MAVYRET | glecaprevir/pibrentasvir | TABLET | 100 mg-40 mg | Y | Y | Quantity Limit |
61958180501 | HARVONI | ledipasvir/sofosbuvir | PELET PACK | 33.75 mg-150 mg | N | Y | Quantity Limit |
61958180502 | HARVONI | ledipasvir/sofosbuvir | PELET PACK | 33.75 mg-150 mg | N | Y | Quantity Limit |
61958180401 | HARVONI | ledipasvir/sofosbuvir | PELET PACK | 45 mg-200 mg | N | Y | Quantity Limit |
61958180402 | HARVONI | ledipasvir/sofosbuvir | PELET PACK | 45 mg-200 mg | N | Y | Quantity Limit |
61958180301 | HARVONI | ledipasvir/sofosbuvir | TABLET | 45 mg-200 mg | N | Y | Quantity Limit |
61958180101 | HARVONI | ledipasvir/sofosbuvir | TABLET | 90 mg-400 mg | N | Y | Quantity Limit |
72626260101 | LEDIPASVIR-SOFOSBUVIR | ledipasvir/sofosbuvir | TABLET | 90 mg-400 mg | N | Y | Quantity Limit |
61958150401 | SOVALDI | sofosbuvir | PELET PACK | 150 mg | N | Y | Quantity Limit |
61958150402 | SOVALDI | sofosbuvir | PELET PACK | 150 mg | N | Y | Quantity Limit |
61958150501 | SOVALDI | sofosbuvir | PELET PACK | 200 mg | N | Y | Quantity Limit |
61958150502 | SOVALDI | sofosbuvir | PELET PACK | 200 mg | N | Y | Quantity Limit |
61958150301 | SOVALDI | sofosbuvir | TABLET | 200 mg | N | Y | Quantity Limit |
61958150101 | SOVALDI | sofosbuvir | TABLET | 400 mg | N | Y | Quantity Limit |
61958240101 | VOSEVI | sofosbuvir/velpatas/voxilaprev | TABLET | 400 mg-100 mg-100 mg | N | Y | Quantity Limit |
61958220501 | EPCLUSA | sofosbuvir/velpatasvir | PELET PACK | 150 mg-37.5 mg | N | Y | Quantity Limit |
61958220502 | EPCLUSA | sofosbuvir/velpatasvir | PELET PACK | 150 mg-37.5 mg | N | Y | Quantity Limit |
61958220401 | EPCLUSA | sofosbuvir/velpatasvir | PELET PACK | 200 mg-50 mg | N | Y | Quantity Limit |
61958220402 | EPCLUSA | sofosbuvir/velpatasvir | PELET PACK | 200 mg-50 mg | N | Y | Quantity Limit |
61958220301 | EPCLUSA | sofosbuvir/velpatasvir | TABLET | 200 mg-50 mg | N | Y | Quantity Limit |
61958220101 | EPCLUSA | sofosbuvir/velpatasvir | TABLET | 400 mg-100 mg | N | Y | Quantity Limit |
72626270101 | SOFOSBUVIR-VELPATASVIR | sofosbuvir/velpatasvir | TABLET | 400 mg-100 mg | Y | Y | Quantity Limit |